Search results
Roche confirmed ambitions to return to sales growth this year on a continued boost from eye drug Vabysmo, after first-quarter sales slipped by 6% on the loss on COVID-19-related revenue. Quarterly sales fell to 14.4 billion Swiss francs ($15.80 billion), the family-controlled drugmaker said in a statement on Wednesday, hurt also by a strong ...
See the company profile for Roche Holding AG (RHHBY) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales Zacks • 14 days ago UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
See Roche Holding AG (RHHBY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
5.85. Enterprise Value/Revenue. 3.49. Enterprise Value/EBITDA. 11.36. -. Upgrade to begin using 40 years of earnings data and get so much more. Build financial models with decades of earnings ...
39.80. 39.52. 39.80. 38.18. 861,900. Discover historical prices for RHHBY stock on Yahoo Finance. View daily, weekly or monthly format back to when Roche Holding AG stock was issued.
1.35 (4.37%) Ex-dividend date. 14 Mar 2024. 1y target est. 37.86. All. News. Press releases. Find the latest Roche Holding AG (RHHBY) stock quote, history, news and other vital information to help you with your stock trading and investing.
